Claritin patent hearing
This article was originally published in The Tan Sheet
Federal Circuit Court of Appeals will hear oral arguments April 8 in Schering-Plough's appeal of lower court ruling that its desloratadine patents are invalid. New Jersey federal judge ruled in August that Schering cannot rely on patent claims covering desloratadine (Clarinex) to keep generic versions of Claritin off the OTC market before 2004 (1"The Tan Sheet" Aug. 12, 2002, p. 3)...
You may also be interested in...
Schering-Plough will not be able to rely on patent claims covering desloratadine to keep generic versions of its Claritin antihistamine off the OTC market before 2004 if a federal judge's ruling is upheld on appeal
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.